Molbio Diagnostics Reports Q1 FY27 Performance, Driven by Truenat Test-Kit Volume Growth

Molbio Diagnostics Reports Q1 FY27 Performance, Driven by Truenat Test-Kit Volume Growth​

Goa, India (September 7, 2026): Molbio Diagnostics Limited, an innovative point-of-care diagnostics company, has announced its unaudited financial results for the quarter ended June 30, 2026. The company reported a significant turnaround in profitability, driven by continued high consumption of its Truenat test kits.

Financial Performance Snapshot​

Molbio Diagnostics delivered a strong performance in the first quarter of the financial year 2027 (Q1 FY27). Total Income for the quarter reached ₹411.48 Cr. The company achieved an EBITDA of ₹103.68 Cr, marking a sharp recovery from the loss of ₹14.50 Cr recorded in Q1 FY26. The PAT stood at ₹52.74 Cr, showing a rebound from the loss of ₹23.94 Cr in the previous year's corresponding quarter.

The consolidated financial highlights across Q1 FY27, Q1 FY26, and Q4 FY26 are summarized below:

Operational Metrics and Growth Drivers​

The Q1 FY27 results were heavily influenced by the volume of Truenat test-kit consumption. The operational key performance indicators (KPIs) reflect movement in sales volume across the three reported quarters.


The positive margin trajectory is attributed to operating leverage on rising test-kit volumes, partially offset by ongoing investment in the international go-to-market structure.

Management Perspective​

Mr. Sriram Natarajan, Executive Director and Chief Executive Officer of Molbio Diagnostics Limited, commented on the performance, noting that FY27 marks a milestone year following the company's listing.

"I am pleased to report that we have begun the year on a strong note, with healthy growth across both revenue and profitability in Q1," Mr. Natarajan stated.

He highlighted that growth is led by test-kit consumption across the 12,500+ Truenat devices sold in 90+ countries.

Mr. Natarajan also provided insight into the company's strategic foundation, noting that the organization entered FY27 with meaningful capacity headroom, as FY26 device and test-kit utilization stood at 42% and 58%, respectively, positioning the company for volume-led scale-up without near-term incremental capital expenditure.

The company's pipeline includes 34 additional assays across 22 diseases, extending beyond infectious diseases into oncology and other non-communicable areas. Internationally, Molbio is deepening its presence across Africa and Southeast Asia, entering Latin America, and advancing regulatory pathways in developed markets, including CE-IVDR for its CTNG Test.

About Molbio Diagnostics Limited​

Molbio Diagnostics Limited is an innovative point-of-care diagnostics company based in Goa. Its flagship product, the Truenat® platform, is a portable, battery-operated real-time PCR platform designed for decentralized molecular testing. Protected by patents in over 100 countries, Truenat® supports molecular testing for 30 diseases through 43 assays. The company has also expanded its portfolio through subsidiaries, including Prognosys Medical Systems and OptraScan Inc., and strategic partnerships with UE Lifesciences, covering areas such as radiology, digital pathology, and breast health screening.

MOLBIO Stock Price Movement​

As of 9:52 AM, shares of Molbio Diagnostics Limited are slipping by 2.67% in live trading, currently hovering near ₹1129.5 as market activity continues. The stock has seen 354,376 shares traded, indicating a notable intraday movement in the healthcare sector.